Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R.

Cells. 2020 Mar 31;9(4). pii: E841. doi: 10.3390/cells9040841. Review.

2.

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein.

McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK.

Acta Neuropathol Commun. 2020 Feb 14;8(1):17. doi: 10.1186/s40478-020-0894-0.

3.

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.

Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V.

Sci Rep. 2019 Jun 10;9(1):8362. doi: 10.1038/s41598-019-42847-x.

4.

Non-steric-zipper models for pathogenic α-synuclein conformers.

Schuman B, Won A, Brand-Arzamendi K, Koprich JB, Wen XY, Howson PA, Brotchie JM, Yip CM.

APL Bioeng. 2018 May 1;2(2):026105. doi: 10.1063/1.5023460. eCollection 2018 Jun.

5.

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB.

J Pharmacol Exp Ther. 2019 Jun;369(3):364-374. doi: 10.1124/jpet.118.255695. Epub 2019 Mar 27.

PMID:
30918068
6.

Generation and Analysis of Viral Vector-Mediated Rodent Models for Parkinson's Disease.

Karikari AA, Koprich JB, Ip CW.

Methods Mol Biol. 2019;1948:271-286. doi: 10.1007/978-1-4939-9124-2_21.

PMID:
30771185
7.

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.

8.

Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2018 Aug;116:180. doi: 10.1016/j.nbd.2018.02.018. Epub 2018 Mar 20. No abstract available.

PMID:
29571591
9.

Update on Molecular Imaging in Parkinson's Disease.

Liu ZY, Liu FT, Zuo CT, Koprich JB, Wang J.

Neurosci Bull. 2018 Apr;34(2):330-340. doi: 10.1007/s12264-017-0202-6. Epub 2017 Dec 27. Review.

10.

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW.

Ann Neurol. 2017 Nov;82(5):856. doi: 10.1002/ana.25066. Epub 2017 Oct 26. No abstract available.

PMID:
28985651
11.

Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.

PMID:
28747776
12.

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2017 Oct;106:133-146. doi: 10.1016/j.nbd.2017.06.009. Epub 2017 Jul 1. Erratum in: Neurobiol Dis. 2018 Mar 20;:.

PMID:
28673739
13.

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW.

Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.

14.

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.

16.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.

PMID:
27776749
17.

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J.

Acta Neuropathol Commun. 2016 Oct 3;4(1):108.

18.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

19.

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J.

Mol Neurobiol. 2016 May;53(4):2258-68. doi: 10.1007/s12035-015-9173-7. Epub 2015 May 14.

PMID:
25972237
20.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM.

Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096.

PMID:
25303957
21.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
22.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
23.

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Review.

PMID:
23319549
24.

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:151-6. doi: 10.1016/j.pnpbp.2012.12.008. Epub 2013 Jan 7.

PMID:
23306217
25.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
26.

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Neuropharmacology. 2012 Oct;63(5):829-36. doi: 10.1016/j.neuropharm.2012.06.012. Epub 2012 Jun 18.

PMID:
22722022
27.

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2012 Aug;342(2):576-85. doi: 10.1124/jpet.112.195693. Epub 2012 May 22.

PMID:
22619253
28.

Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat.

Thompson VB, Koprich JB, Chen EY, Kordower JH, Terpstra BT, Lipton JW.

Neurotoxicol Teratol. 2012 Jan-Feb;34(1):206-13. doi: 10.1016/j.ntt.2011.09.005. Epub 2011 Sep 28.

29.

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

J Neurosci. 2011 May 11;31(19):7190-8. doi: 10.1523/JNEUROSCI.1171-11.2011.

30.

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.

Mov Disord. 2011 Jun;26(7):1225-33. doi: 10.1002/mds.23631. Epub 2011 Apr 4.

PMID:
21465551
31.

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM.

PLoS One. 2011 Mar 7;6(3):e17698. doi: 10.1371/journal.pone.0017698.

32.

The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration.

Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O.

J Neurosci. 2010 Dec 1;30(48):16091-101. doi: 10.1523/JNEUROSCI.2400-10.2010.

33.

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):207.e9-19. doi: 10.1016/j.neurobiolaging.2010.09.011. Epub 2010 Nov 3.

PMID:
21051107
35.

Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

Chung CY, Koprich JB, Hallett PJ, Isacson O.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22474-9. doi: 10.1073/pnas.0912193106. Epub 2009 Dec 10.

36.

New insights into the organization of the basal ganglia.

Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM.

Curr Neurol Neurosci Rep. 2009 Jul;9(4):298-304.

PMID:
19515282
37.
38.

Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.

Koprich JB, Reske-Nielsen C, Mithal P, Isacson O.

J Neuroinflammation. 2008 Feb 27;5:8. doi: 10.1186/1742-2094-5-8.

39.
40.

MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment.

Campbell NG, Koprich JB, Kanaan NM, Lipton JW.

Neurotoxicol Teratol. 2006 Jul-Aug;28(4):459-65. Epub 2006 Jun 8.

PMID:
16905291
41.

Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice.

Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ.

J Neurosci. 2005 Nov 2;25(44):10220-9.

42.

Ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice.

He B, Counts SE, Perez SE, Hohmann JG, Koprich JB, Lipton JW, Steiner RA, Crawley JN, Mufson EJ.

Neuroscience. 2005;133(2):371-80. Erratum in: Neuroscience. 2007 Feb 23;144(4):1544.

PMID:
15885921
44.

Prenatal cocaine administration increases glutathione and alpha-tocopherol oxidation in fetal rat brain.

Lipton JW, Gyawali S, Borys ED, Koprich JB, Ptaszny M, McGuire SO.

Brain Res Dev Brain Res. 2003 Dec 30;147(1-2):77-84.

PMID:
14741753
45.

Supplemental Content

Loading ...
Support Center